June 5, 2017 / 8:09 PM / a month ago

BRIEF-Lysogene: Clinical Hold Issued For AAVance Phase 2/3 Trial

June 5 (Reuters) - LYSOGENE SA:

* ANNOUNCES IMPORTANT UPDATES ON AAVANCE PHASE 2/3 CLINICAL TRIAL WITH LYS-SAF302 IN MPS IIIA

* CLINICAL HOLD WAS ISSUED FOR CLINICAL TRIAL AAVANCE (NCT03612869), A GLOBAL PHASE 2/3 CLINICAL TRIAL OF LYS-SAF302

* TO DATE, 19 OUT OF 20 PATIENTS HAVE BEEN TREATED

* PRIMARY AND SECONDARY TRIAL ENDPOINTS ARE BASED ON ANALYSES OF THESE 19 PATIENTS ALREADY ENROLLED

* THERE IS NO ANTICIPATED IMPACT ON CURRENT CLINICAL TRIAL TIMELINES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below